Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | PHGDH | O43175 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18619500 | 1.00 | POLB (0.59) | POLBHSD17B10KDM4EALDH1A1PHGDH | |
| SCHEMBL3768409 | 0.98 | POLB (0.56) | POLBHSD17B10KDM4EALDH1A1PHGDH | |
| SCHEMBL21482671 | 0.94 | POLB (0.54) | POLBHSD17B10KDM4EALDH1A1PHGDH | |
| SCHEMBL65252 | 0.93 | POLB (0.52) | POLBHSD17B10KDM4EALDH1A1PHGDH | |
| SCHEMBL65329 | 0.89 | HRH3 (0.47) | POLBHSD17B10KDM4EALDH1A1PHGDH | |
| SCHEMBL1507253 | 0.88 | HRH3 (0.52) | POLBHSD17B10KDM4EALDH1A1HRH3 | |
| SCHEMBL27739891 | 0.84 | HRH3 (0.64) | POLBHSD17B10KDM4EALDH1A1PHGDH | |
| SCHEMBL2553841 | 0.84 | HRH3 (0.44) | POLBHSD17B10KDM4EALDH1A1HRH3 | |
| SCHEMBL18125956 | 0.84 | CHRM1 (0.50) | POLBHSD17B10KDM4EALDH1A1PHGDH | |
| SCHEMBL3598735 | 0.83 | KDM4E (0.45) | POLBHSD17B10KDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | claimed |
| CN-101365698-A | 2-urea-4-phenylthiazole derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2009-02-11 | — | — | CN | claimed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | claimed |
| CN-1976904-A | Pyridazin-3 (2H) -one derivatives and their use as PDE4 inhibitors | ALMIRALL LAB (ES) | 2007-06-06 | — | — | CN | claimed |
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| US-11926619-B2 | Certain pladienolide compounds and methods of use | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2024-03-12 | — | — | US | disclosed |
| EP-3253752-B1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11053242-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200262834-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2020-08-20 | — | — | US | disclosed |
| US-9988382-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-A]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988382-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-A]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9714246-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714246-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160289226-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289226-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| CN-101365698-A | 2-urea-4-phenylthiazole derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2009-02-11 | — | — | CN | disclosed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | disclosed |
| CN-1976904-A | Pyridazin-3 (2H) -one derivatives and their use as PDE4 inhibitors | ALMIRALL LAB (ES) | 2007-06-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289226-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | SLC18A2, SLC6A2, SLC18A1 | POLB 1862/4885HSD17B10 824/4885KDM4E 2258/4885 |
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | POLB 1222/4885HSD17B10 854/4885KDM4E 2775/4885 |
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | SNRPE, SNRPB2, DDX21 | POLB 1292/4885HSD17B10 738/4885KDM4E 2035/4885 |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PKD2, QPCT, CCNT2 | POLB 4267/4885HSD17B10 1861/4885KDM4E 114/4885 |
| US-11053242-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | SLC18A2, SLC6A2, SLC18A1 | POLB 1862/4885HSD17B10 824/4885KDM4E 2258/4885 |
| US-20200262834-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | SLC18A2, SLC6A2, SLC18A1 | POLB 1862/4885HSD17B10 824/4885KDM4E 2258/4885 |
| US-11926619-B2 | Certain pladienolide compounds and methods of use | PLAAT5, PLAAT3, PLAAT4 | POLB 1222/4885HSD17B10 854/4885KDM4E 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.